

Tuesday 20 May 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Wednesday 7 May 2025. I am pleased to confirm the following.

Primary Requests

Stage 3 or 4 Colorectal Cancer in Postpartum Women (2017–2020): For female patients under 45 years old diagnosed with stage 3 or 4 colorectal/bowel cancer (any subtype, e.g., sigmoid adenocarcinoma) who were postpartum (having given birth within 12 months prior to diagnosis): a. Total number diagnosed. b. Number who died within 12 months of diagnosis (exact number or range if <5). c. Total number of deaths up to 31 December 2020. d. Survival duration (in months) from diagnosis to death for each deceased case (anonymised).

Stage 3 or 4 Colorectal Cancer in Postpartum Women (2021–2024): The same data as above (1a–1d) for female patients under 45 diagnosed with stage 3 or 4 colorectal/bowel cancer who were postpartum, except total deaths (2c) up to 31 December 2024.

All Stage 3 or 4 Cancers (2017–2020): For all patients (all ages, all genders) diagnosed with stage 3 or 4 cancer (any type): a. Total number diagnosed. b. Number who died within 12 months of diagnosis (exact number or range if <5). c. Total number of deaths up to 31 December 2020. d. Survival duration (in months) from diagnosis to death for each deceased case (anonymised).

All Stage 3 or 4 Cancers (2021–2024): The same data as above (3a–3d) for patients diagnosed with stage 3 or 4 cancer (any type), except total deaths (4c) up to 31 December 2024.

Supplementary Requests

To investigate potential contributing factors (e.g., diagnostic delays, environmental triggers), please provide the following anonymised details for patients in Requests 1 and 2 (postpartum women under 45 with stage 3 or 4 colorectal cancer):

COVID-19 Vaccination Status: If available, provide: a. Number of patients vaccinated (anonymised). b. Vaccine type (e.g., Pfizer, AstraZeneca) and number of doses. c. Timing of vaccination relative to pregnancy or diagnosis (e.g., pre-pregnancy, during pregnancy, post-diagnosis).

Diagnosis Timing: Month and year of diagnosis for each case (anonymised).

Concerning the Stage and Progression of Cancer: The cancer stage at the time of diagnosis (Stage 3 or 4) for each case (anonymised). If any cases were initially diagnosed at Stage 1 or 2 but later progressed to Stage 3 or 4, please indicate the number of such cases

Treatment and Outcomes: Whether patients received treatment (e.g., surgery, chemotherapy) and outcomes (e.g., remission, progression, death), anonymised.

Genetic Testing or Biopsy Analysis: Whether cases underwent tumour genetic testing (e.g., APC, P53, MMR, KRAS, BRAF) or biopsy analysis for contaminants (e.g., SV40 promoter, plasmid ORI, spike protein). If so, provide anonymised results (e.g., mutation types, presence of contaminants).

Reporting and Referrals: a. Whether cases or deaths were reported to the MHRA (e.g., Yellow Card scheme) or MBRRACE-UK. b. Whether deaths were referred to the coroner, including number and reasons (anonymised).

Please see attached document.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.